Analysis

June’s top stories: NIH’s Phase I/II trial for chikungunya, Boehringer & Eli Lilly’s empagliflozin trial

June’s top stories: NIH’s Phase I/II trial for chikungunya, Boehringer & Eli Lilly’s empagliflozin trial

May's top stories: Funders and NGOs agreed on new standards, Actinogen's Xanamem in Phase II

May's top stories: Funders and NGOs agreed on new standards, Actinogen's Xanamem in Phase II

April's top stories: NIAID's Phase II/IIb Zika vaccine trial, Boehringer's nintedanib in Phase III trial

April's top stories: NIAID's Phase II/IIb Zika vaccine trial, Boehringer's nintedanib in Phase III trial

March's top stories: Cancer Research UK's pancreatic cancer trials, Novartis' Cosentyx in psoriasis

March's top stories: Cancer Research UK's pancreatic cancer trials, Novartis' Cosentyx in psoriasis

February's top stories: Merck's Phase III HIV-1 trial results, NIH's Phase I AGS-v vaccine trial

February's top stories: Merck's Phase III HIV-1 trial results, NIH's Phase I AGS-v vaccine trial

January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk

January's top stories: TG Therapeutics' Phase II trial, antidepressant hip fracture risk

2016: The year's biggest Drug Development Technology stories

2016: The year's biggest Drug Development Technology stories

November’s top stories: Wellcome’s clinical trial network, Eli Lilly’s Alzheimer disease drug trial

November’s top stories: Wellcome’s clinical trial network, Eli Lilly’s Alzheimer disease drug trial

October’s top stories: Eurocine Vaccines initiated influenza vaccine study, IVF usage led to conceiving male child

October’s top stories: Eurocine Vaccines initiated influenza vaccine study, IVF usage led to conceiving male child

September's top stories: Oncternal begins TK216 trial, Medical cannabis trials begin in Canada

September's top stories: Oncternal begins TK216 trial, Medical cannabis trials begin in Canada

August's top stories: Gradalis' Phase I breast cancer trial, Biothera and Merck conducted combination cancer immunotherapy trials

August's top stories: Gradalis' Phase I breast cancer trial, Biothera and Merck conducted combination cancer immunotherapy trials

Pharma Technology Focus – Issue 50

Pharma Technology Focus – Issue 50

July's top stories: GBT's Phase II1 trial GBT440, Merck's Phase III trial ONCEMRK of Isentress

July's top stories: GBT's Phase II1 trial GBT440, Merck's Phase III trial ONCEMRK of Isentress

June's top stories: Bayer reported positive results of RESORCE trial, TapImmune initiated Phase II trial of TPIV 200

June's top stories: Bayer reported positive results of RESORCE trial, TapImmune initiated Phase II trial of TPIV 200

May's top stories: ProMedica began human stem cell trial, Cerulean dosed in Phase l/ll combination trial

May's top stories: ProMedica began human stem cell trial, Cerulean dosed in Phase l/ll combination trial

April's top stories: SynbiCITE's synthetic biology foundry, Omeros's phase II clinical trial of OMS721

April's top stories: SynbiCITE's synthetic biology foundry, Omeros's phase II clinical trial of OMS721

March's top stories: Tracon's Phase IbTRC105 clinical trial, ADC begins ADCT-402 trial

March's top stories: Tracon's Phase IbTRC105 clinical trial, ADC begins ADCT-402 trial

Pharma Technology Focus – Issue 45

Pharma Technology Focus – Issue 45

February's top stories: 60% of trial results not shared, Dilaforette-AGU team-up

February's top stories: 60% of trial results not shared, Dilaforette-AGU team-up

Pharma Technology Focus - Issue 44

Pharma Technology Focus - Issue 44

January's top stories: Profectus Ebola trial, AstraZeneca-Incyte lung cancer drug

January's top stories: Profectus Ebola trial, AstraZeneca-Incyte lung cancer drug